Download PDF
Semin Respir Crit Care Med 2004; 25: 33-43
DOI: 10.1055/s-2004-829643
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Rationale for Investigation of Epidermal Growth Factor Receptor Inhibitors in Definitive Treatment of Locally Advanced Non-Small Cell Lung Cancer and Head and Neck Cancer

Hak Choy1 , Dong Wook Kim2
  • 1Department of Radiation Oncology, The University of Texas Southwestern, Dallas, Texas
  • 2Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
Further Information

Publication History

Publication Date:
22 June 2004 (online)

    Permissions and Reprints

Designing targeted therapies has become an important field in cancer therapeutics. The epidermal growth factor receptor (EGFR) is a molecular target that has gained immense attention as preclinical and clinical studies have supported its potential role for therapy of a variety of cancers, including non-small cell lung cancer (NSCLC) and head and neck (HN) cancer. Several compounds that specifically inhibit EGFR have been developed, including ZD1839, C225, and OSI-774. Interestingly, studies suggesting a potential role for EGFR inhibitors as an adjunct to the current combined-modality approach for therapy of NSCLC and HN cancer have been performed in the preclinical and clinical setting. Therefore, determining the potential of EGFR inhibitors to improve the efficacy of standard combined-modality regimens (chemotherapy/radiation therapy ± surgery) for NSCLC and HN cancer patients is of the utmost importance. An overview of the rationale and the ongoing/proposed studies aimed at determining the role for EGFR inhibitors in combination with radiation therapy for NSCLC and HN cancer patients will be presented.

KEYWORDS

Non-small cell lung cancer (NSCLC) - head and neck cancer - epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor - ZD1839 - OSI-774 - C225

REFERENCES

  • 1 Bonner J A, Raisch K P, Trummell H Q et al.. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers.  J Clin Oncol. 2000;  18(suppl) S47-S53
    PubMedGoogle Scholar
  • 2 Dassonville O, Formento J L, Francoual M et al.. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.  J Clin Oncol. 1993;  11 1873-1878
    PubMedGoogle Scholar
  • 3 Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy.  Oncologist. 2002;  7(suppl 4) S2-S8
    PubMedGoogle Scholar
  • 4 Contessa J N, Reardon D B, Todd D et al.. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells.  Clin Cancer Res. 1999;  5 405-411
    PubMedGoogle Scholar
  • 5 Sheridan M T, O'Dwyer T, Seymour C B et al.. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck.  Radiat Oncol Investig. 1997;  5 180-186
    CrossrefPubMedGoogle Scholar
  • 6 Akimoto T, Hunter N R, Buchmiller L et al.. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.  Clin Cancer Res. 1999;  5 2884-2890
    PubMedGoogle Scholar
  • 7 Bowers G, Reardon D, Hewitt T et al.. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells.  Oncogene. 2001;  20 1388-1397
    CrossrefPubMedGoogle Scholar
  • 8 Harari P M, Huang S M. Modulation of molecular targets to enhance radiation.  Clin Cancer Res. 2000;  6 323-325
    PubMedGoogle Scholar
  • 9 Huang S M, Li J, Armstrong E A et al.. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).  Cancer Res. 2002;  62 4300-4306
    PubMedGoogle Scholar
  • 10 Schmidt-Ullrich R K, Mikkelson R B, Dent P et al.. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation.  Oncogene. 1997;  15 1191-1197
    CrossrefPubMedGoogle Scholar
  • 11 Kim E S, Khuri F R, Herbst R S. Epidermal growth factor receptor biology (IMC-C225).  Curr Opin Oncol. 2001;  13 506-513
    CrossrefPubMedGoogle Scholar
  • 12 Ciardiello F, Caputo R, Bianco R et al.. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.  Clin Cancer Res. 2001;  7 1459-1465
    PubMedGoogle Scholar
  • 13 Ciardiello F, Caputo R, Bianco R et al.. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor- selective tyrosine kinase inhibitor.  Clin Cancer Res. 2000;  6 2053-2063
    PubMedGoogle Scholar
  • 14 Raben D, Helfrich B A, Chan D et al.. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.  Semin Oncol. 2002;  29(suppl 4) S37-S46
    CrossrefPubMedGoogle Scholar
  • 15 Magne N, Fischel J L, Dubreuil A et al.. Sequence-dependent effects of ZD1839 (“Iressa”) in combination with cytotoxic treatment in human head and neck cancer.  Br J Cancer. 2002;  86 819-827
    CrossrefPubMedGoogle Scholar
  • 16 Moyer J D, Barbacci E G, Iwata K K et al.. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.  Cancer Res. 1997;  57 4838-4848
    PubMedGoogle Scholar
  • 17 Pollack V A, Savage D M, Baker D A et al.. Inhibition of epidermal growth factor receptor- associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.  J Pharmacol Exp Ther. 1999;  291 739-748
    PubMedGoogle Scholar
  • 18 Herbst R S, Langer C J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.  Semin Oncol. 2002;  29(suppl 4) S27-S36
    PubMedGoogle Scholar
  • 19 Harari P M, Huang S M. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.  Int J Radiat Oncol Biol Phys. 2001;  49 427-433
    CrossrefPubMedGoogle Scholar
  • 20 Nasu S, Ang K K, Fan Z et al.. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability.  Int J Radiat Oncol Biol Phys. 2001;  51 474-477
    CrossrefPubMedGoogle Scholar
  • 21 Huang S M, Harari P M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.  Clin Cancer Res. 2000;  6 2166-2174
    PubMedGoogle Scholar
  • 22 Bianco C, Bianco R, Tortora G et al.. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.  Clin Cancer Res. 2000;  6 4343-4350
    PubMedGoogle Scholar
  • 23 Milas L, Mason K, Hunter N et al.. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.  Clin Cancer Res. 2000;  6 701-708
    PubMedGoogle Scholar
  • 24 Wu H, Kim J, Cao Q et al.. Combined modality therapy of NCI-H460 human lung cancer using epidermal growth factor receptor inhibitor, OSI-774, and ionizing radiation in vitro and in vivo [abstract 1031].  Int J Radiat Oncol Biol Phys. 2002;  54(suppl 2) 176
    CrossrefPubMedGoogle Scholar
  • 25 Kusaba H, Tamura T, Nakagawa K et al.. A phase I intermittent dose-escalation trial of ZD 1839 (Iressa) in Japanese pts with solid malignant tumours. Proceedings of the 11th NCI-EORTC-AACR Symposium [abstract L381].  Clin Cancer Res. 2000;  6(suppl 11)
    PubMedGoogle Scholar
  • 26 Ferry D, Hammond L, Ranson M et al.. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) shows evidence of good tolerability and activity: final results from a phase I study [abstract 5E].  Proc Am Soc Clin Oncol. 2000;  19 3a
    PubMedGoogle Scholar
  • 27 Baselga J, Rischin D, Ranson M et al.. Pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types.  J Clin Oncol. 2002;  20 4292-4302
    CrossrefPubMedGoogle Scholar
  • 28 Goss G et al.. Phase I, dose escalation, pharmacokinetics (PK) and pharmacodynamic (PD) study of ZD 1839: NCIC CTG IND.122. Proceedings of the 11th NCI-EORTC-AACR Symposium [abstract 382].  Clin Cancer Res. 2000;  6(suppl)
    PubMedGoogle Scholar
  • 29 Baselga J, Pfister D, Cooper M R et al.. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.  J Clin Oncol. 2000;  18 904-914
    PubMedGoogle Scholar
  • 30 Hidalgo M, Siu L L, Nemunaitis J et al.. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.  J Clin Oncol. 2001;  19 3267-3279
    PubMedGoogle Scholar
  • 31 Fukuoka M, Yano S, Giaccone G et al.. Final results from a phase II trial of ZD1839 (“Iressa”) for patients with advanced non-small-cell lung cancer (IDEAL 1) [abstract 1188].  Proc Am Soc Clin Oncol. 2002;  21 298a
    PubMedGoogle Scholar
  • 32 Kris M G, Natale R B, Herbst R S et al.. A phase II trial of ZD1839 (“Iressa”) in advanced non-small cell lung cancer (NSCLC) patients who failed platinum- and docetaxel-based regimens (IDEAL 2) [abstract 1166].  Proc Am Soc Clin Oncol. 2002;  21 292a
    PubMedGoogle Scholar
  • 33 Douillard J-Y, Giaccone G, Horai T et al.. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 (“Iressa”) (IDEAL 1) [abstract 1195].  Proc Am Soc Clin Oncol. 2002;  21 299a
    PubMedGoogle Scholar
  • 34 Natale R B, Skarin A, Maddox A-M et al.. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 (“Iressa”) in IDEAL 2 [abstract 1167].  Proc Am Soc Clin Oncol. 2002;  21 292a
    PubMedGoogle Scholar
  • 35 Johnson D H. Iressa disappoints in NSCLC. 27th ESMO Congress, Nice 18-22 October 2002.  Eur J Cancer. 2003;  38 1
    PubMedGoogle Scholar
  • 36 Senzer N N, Soulieres D, Siu L et al.. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck [abstract 6].  Proc Am Soc Clin Oncol. 2001;  20 2a
    PubMedGoogle Scholar
  • 37 Finkler N, Gordon A, Crozier M et al.. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma [abstract 831].  Proc Am Soc Clin Oncol. 2001;  20 208a
    PubMedGoogle Scholar
  • 38 Perez-Soler R, Chachoua A, Huberman M et al.. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract 1235].  Proc Am Soc Clin Oncol. 2001;  20 310a
    PubMedGoogle Scholar
  • 39 Kim E S, Mauer A M, Fossella F V et al.. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC) [abstract 1168].  Proc Am Soc Clin Oncol. 2002;  21 293a
    PubMedGoogle Scholar
  • 40 Baselga J, Trigo J M, Bourhis J et al.. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen [abstract 900].  Proc Am Soc Clin Oncol. 2002;  21 226a
    PubMedGoogle Scholar
  • 41 Burtness B A, Li Y, Flood W et al.. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC) [abstract 901].  Proc Am Soc Clin Oncol. 2002;  21 226a
    PubMedGoogle Scholar
  • 42 Cohen E EW, Rosen F, Dekker A et al.. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) [abstract 899].  Proc Am Soc Clin Oncol. 2002;  21 225a
    PubMedGoogle Scholar
  • 43 Robert F, Ezekiel M P, Spencer S A et al.. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.  J Clin Oncol. 2001;  19 3234-3243
    PubMedGoogle Scholar
  • 44 Gandara D R, Lovato L C, Albain K S et al.. Prolonged survival in pathologic stage IIIB non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy followed by consolidation docetaxel: a phase II study (S9504) of the Southwest Oncology Group (SWOG) [abstract 1916].  Proc Am Soc Clin Oncol. 2000;  19 490a
    PubMedGoogle Scholar

Hak ChoyM.D. 

Department of Radiation Oncology, The University of Texas Southwestern

5801 Forest Park Rd.

Dallas, TX 75390-9183

Email: Hak.Choy@UTSouthwestern.edu

      >